Clinical Trial

Pulmonary Hypertension SOLAR

Study acronym: PH SOLAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2021-02-26; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2022-10-05
Trial Details
NCT Number NCT04778046
Lead Sponsor Bastiaan Driehuys
Conditions Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Enrollment 30 participants
Start Date 2023-11-08
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-24